drugset / Trial / NCT03351166

A Study of Molidustat for Correction of Renal Anemia in Dialysis Subjects

NCT03351166

Phase 3 Completed 25 enrolled Bayer
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of Molidustat in dialysis subjects with renal anemia who are not treated with Erythropoiesis-Stimulating Agents (ESAs)

Timeline

Start
2018-01-22
Primary completion
2018-10-23
Completion
2018-11-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Molidustat Small molecule 75 mg Oral